COVID-19 – A vascular disease

[1]  E. Carreras,et al.  Preeclampsia-like Syndrome Induced by Severe COVID-19: A Prospective Observational Study , 2021, Obstetric Anesthesia Digest.

[2]  Benjamin S. Glicksberg,et al.  Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19 , 2020, Journal of the American College of Cardiology.

[3]  Benjamin S. Glicksberg,et al.  Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19 , 2020, Journal of the American College of Cardiology.

[4]  P. Libby,et al.  COVID-19 is, in the end, an endothelial disease , 2020, European heart journal.

[5]  Kade Birkeland,et al.  Venous Thromboembolism in Hospitalized COVID-19 Patients: Systematic Review , 2020, Interactive journal of medical research.

[6]  W. Ge,et al.  Incidence of Venous Thromboembolism in Hospitalized Coronavirus Disease 2019 Patients: A Systematic Review and Meta-Analysis , 2020, Frontiers in Cardiovascular Medicine.

[7]  P. Libby,et al.  Role for Anti-Cytokine Therapies in Severe Coronavirus Disease 2019 , 2020, Critical care explorations.

[8]  Eike Nagel,et al.  Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19) , 2020, JAMA cardiology.

[9]  G. d’Ettorre,et al.  Nox2 activation in Covid-19 , 2020, Redox Biology.

[10]  C. D. Dela Cruz,et al.  Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study , 2020, The Lancet Haematology.

[11]  J. Mocco,et al.  COVID-19 Is an Independent Risk Factor for Acute Ischemic Stroke , 2020, American Journal of Neuroradiology.

[12]  Qingbo Xu,et al.  In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19 , 2020, Cell Metabolism.

[13]  Y. Kanthi,et al.  COVID–19-associated coagulopathy: An exploration of mechanisms , 2020, Vascular medicine.

[14]  E. Carreras,et al.  Pre‐eclampsia‐like syndrome induced by severe COVID‐19: a prospective observational study , 2020, BJOG : an international journal of obstetrics and gynaecology.

[15]  P. Libby,et al.  Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients , 2020, Pharmacology & Therapeutics.

[16]  Axel Haverich,et al.  Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. , 2020, The New England journal of medicine.

[17]  F. Collins,et al.  Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): An Unprecedented Partnership for Unprecedented Times. , 2020, JAMA.

[18]  M. Trauner,et al.  Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome: Results From a Prospective, Single-Center, Clinicopathologic Case Series , 2020, Annals of Internal Medicine.

[19]  Thomas Song,et al.  Acute Pulmonary Embolism and COVID-19 , 2020, Radiology.

[20]  P. Theocharis,et al.  Hyperinflammatory shock in children during COVID-19 pandemic , 2020, The Lancet.

[21]  Mickaël Ohana,et al.  High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study , 2020, Intensive Care Medicine.

[22]  B. Bozkurt,et al.  Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19 , 2020, Journal of Cardiac Failure.

[23]  G. Mancia,et al.  Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19 , 2020, The New England journal of medicine.

[24]  Thomas J Oxley,et al.  Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young , 2020, The New England journal of medicine.

[25]  Binita Shah,et al.  ST-Segment Elevation in Patients with Covid-19 — A Case Series , 2020, The New England journal of medicine.

[26]  M. Netea,et al.  Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure , 2020, Cell Host & Microbe.

[27]  D. Morrow,et al.  COVID-19 for the Cardiologist , 2020, JACC: Basic to Translational Science.

[28]  W. Gong,et al.  Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. , 2020, JAMA cardiology.

[29]  Mandeep R. Mehra,et al.  COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal , 2020, The Journal of Heart and Lung Transplantation.

[30]  Bo Diao,et al.  Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19) , 2020, Frontiers in Immunology.

[31]  T. Münzel,et al.  Nox2+ Myeloid cells drive vascular inflammation and endothelial dysfunction in heart failure after myocardial infarction via angiotensin II receptor type 1. , 2020, Cardiovascular research.

[32]  Jing Yuan,et al.  Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury , 2020, Science China Life Sciences.

[33]  É. Azoulay,et al.  Immune Consequences of Endothelial Cells' Activation and Dysfunction During Sepsis. , 2020, Critical care clinics.

[34]  N. Leeper,et al.  Thrombotic Regulation From the Endothelial Cell Perspectives. , 2018, Arteriosclerosis, thrombosis, and vascular biology.

[35]  A. Hidalgo,et al.  Neutrophils as effectors of vascular inflammation , 2018, European journal of clinical investigation.

[36]  S. Lewin,et al.  Endosomal NOX2 oxidase exacerbates virus pathogenicity and is a target for antiviral therapy , 2017, Nature Communications.

[37]  Mark Chappell,et al.  A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury , 2005, Nature Medicine.

[38]  K. Mann,et al.  Statins and Blood Coagulation , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[39]  G. Navis,et al.  Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis , 2004, The Journal of pathology.

[40]  K. Nakagawa,et al.  HMG CoA reductase inhibitor suppresses the expression of tissue factor and plasminogen activator inhibitor-1 induced by angiotensin II in cultured rat aortic endothelial cells. , 2003, Thrombosis research.

[41]  A. Brasier,et al.  Vascular inflammation and the renin-angiotensin system. , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[42]  U. Laufs,et al.  Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. , 1998, Circulation.